Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | NPY1R | P25929 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | THRB | P10828 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24153613 | 0.95 | NPY1R (0.36) | KMT2ASMN1; SMN2HTR1ANPY1RLMNA | |
| SCHEMBL24153499 | 0.94 | HTR1A (0.39) | HTR1ANPY1R | |
| SCHEMBL24938892 | 0.94 | NPY1R (0.41) | SMN1; SMN2HTR1ANPY1RLMNATHRB | |
| SCHEMBL24939891 | 0.94 | LMNA (0.42) | KMT2ASMN1; SMN2HTR1ANPY1RLMNA | |
| SCHEMBL24939973 | 0.93 | NPY1R (0.36) | HTR1ANPY1RLMNATHRBMAPT | |
| SCHEMBL24939892 | 0.93 | LMNA (0.38) | HTR1ANPY1RLMNATHRBMAPT | |
| SCHEMBL24153600 | 0.92 | MCHR1 (0.37) | HTR1ANPY1R | |
| SCHEMBL24153472 | 0.92 | HTR1A (0.39) | HTR1ANPY1R | |
| SCHEMBL24939924 | 0.91 | L3MBTL1 (0.41) | KMT2ASMN1; SMN2NPY1RPDE5AMAPT | |
| SCHEMBL24938971 | 0.91 | NPY1R (0.39) | HTR1ANPY1RLMNATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | HOLOSMEDIC (KR) | 2023-01-19 | — | — | US | disclosed |
| WO-2021261969-A1 | PREPARATION METHOD FOR NOVEL COMPOUND | 홀로스메딕 주식회사 | 2021-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019094-A1 | NOVEL COMPOUND AND PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF CANCER COMPRISING SAME | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, ABCC1 | KMT2A 2394/4885SMN1; SMN2 3242/4885HTR1A 4854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.